AbbVie Inc.
AbbVie Completes Acquisition of ImmunoGen
Summary
AbbVie Inc. completed its acquisition of ImmunoGen Inc. on February 12, 2024, adding the antibody-drug conjugate ELAHERE for platinum-resistant ovarian cancer to its portfolio. The acquisition is expected to be accretive to AbbVie's diluted EPS beginning in 2027. AbbVie updated its 2024 first-quarter adjusted diluted EPS guidance to $2.26-$2.30, reflecting a $0.04 per share impact from the acquisition.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement